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disease.
2. Case
A 68-year-old Caucasian female developed shortness of breath in
May 2010. Computed tomography (CT) of the chest, abdomen and pel-Keywords:
Nonbacterial thrombotic endocarditis
Valvular vegetations
Embolic stroke
Ovarian clear cell carcinoma
Ovarian cancer
Anticoagulation1. Introduction
Nonbacterial thrombotic endocarditis (NBTE) is characterized byde-
position of sterile platelet and ﬁbrin thrombi on valvular structures,
which are prone to embolism andmost commonly involve the cerebro-
vascular circulation (González et al., 1991; Sørensen et al., 2000). NBTE
is not uncommon in patients with advanced mucin-secreting ovarian
adenocarcinomas, and a few case reports have shown an association
with ovarian clear cell cancer (OCCC) (Heit et al., 2000; Aryana et al.,
2006; Devulapalli et al., 2012; Naoi et al., 2013). In North America and
Europe, OCCC is the secondmost common histologic subtype of epithe-
lial ovarian cancer, with an estimated prevalence of 1–12% (Goff et al.,
1996). Advanced OCCC carries a poor prognosis and is associated with
an elevated risk of vascular thrombotic events, with as many as 40% of
patients experiencing thromboembolic events (Goff et al., 1996). Here
we report on a patient with metastatic OCCC presenting with embolicology Service, Department of
E. 66th Street, New York, NY
. This is an open access article undervis revealed a pulmonary embolus (PE) in the right lower lobe pulmo-
nary artery, a 16.6 × 13.1 cm pelvic mass, retroperitoneal
lymphadenopathy, right pleural effusion, and a right pleural-based
mass measuring 1.8 × 1.3 cm. CA-125 tumor marker was elevated at
358 U/mL. The patient was placed on dalteparin for PE management.
One month later she underwent exploratory laparotomy with total ab-
dominal hysterectomy, bilateral salpingo-oophorectomy, bilateral
ureterolysis, para-aortic lymph node dissection, ablation of diaphrag-
matic nodules, and liver right lobe wedge resection. Pathology revealed
stage IVB OCCC. Of note, the patient underwent prophylactic inferior
vena cava ﬁlter placement preoperatively and was started on
enoxaparin following complete gross surgical debulking.
Following surgery, the patient enrolled in Gynecologic Oncology
Group (GOG) 252, a phase III trial of bevacizumab with intravenous
(IV) versus intraperitoneal (IP) chemotherapy, and received six cycles
of IP carboplatin at an area under the curve (AUC) of 6 on day 1 and
weekly IV paclitaxel 80 mg/m2 on days 1, 8, and 15. With the start of
cycle 2 she also received IV bevacizumab at 15 mg/kg once every
3 weeks. After the last dose of combination chemotherapy, the patient
was maintained on IV bevacizumab at 15 mg/kg once every 3 weeks
for a total of 16 additional cycles, which she completed in 12/2011.
One a month after completion of maintenance bevacizumab thera-
py, CT revealed progression of disease in liver segment 4B and the
right pleura. The patient underwent a video-assisted thoracoscopic sur-
gery (VATS), thoracic lymphadenectomy, open celiac lymphadenecto-
my, and partial hepatectomy. Postoperatively, it was recommended
that she restarts enoxaparin, but she elected to forego further
anticoagulation therapy. Following secondary debulking, the patient
was treated with weekly paclitaxel and investigational VTX-2337 from
8/2012 to 11/2012, followed by carboplatin and liposomal doxorubicin
from 11/12 to 2/13, and gemcitabine and bevacizumab in 3/13, but
her disease continued to progress.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Lab values on presentation to Emergency Department.
Variable Patient values Normal range
WBC 4.7 × 103 cell/μL 3.9–10.7 × 103 cells/μL
Hemoglobin 7.9 g/dL 12–16 g/dL
Platelets 68/nL 150–450/nL
Absolute neutrophil count 3.52 1.5–8.0 (1500 to 8000/mm3)
BUN 19 mg/dL 7–18 mg/dL
Creatinine 1.0 mg/dL 0.6–1.2 mg/dL
Potassium 4.4 mEq/L 3.5–5.0 mEq/L
Sodium 138 mEq/L 135–145 mEq/L
Magnesium 1.5 mEq/L 1.5–2.0 mEq/L
Calcium 8.8 mg/dL 8.4–10.2 mg/dL
PT 14.0 s 11–13 s
PTT 29.8 s 25–35 s
INR 1.14 0.8 to 1.2
C-reactive protein 8.6 mg/dL b0.5 mg/dL
ESR 15 mm/h 0–20 mm/h
LDL 98 mg/dL b130 mg/dL
Vitamin B12 187 pg/mL 200–800 pg/mL
Folate 12.4
TSH 2.33 uU/ml 0.5–4.6 uU/ml
CA125 914 U/mL b35 U/mL
WBC, white blood cell count; BUN, blood urea nitrogen; PT, prothrombin time; PTT, partial
thromboplastin time; INR, international normalized ratio; ESR, erythrocyte sedimentation
rate; LDL, low-density lipoprotein; TSH, thyroid-stimulating hormone.
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presented with a 3-day history of headaches and sudden onset visual
changes. She described “blotches” in her visual ﬁeld and impairment
in her peripheral vision. Within hours, she developed confusion, with
the inability to remember any events of the prior 24 h. Neurological
exam revealed a left homonymous hemianopsia and retrograde short-
term memory loss. She was afebrile and her vital signs revealed: pulse
96, blood pressure 139/56, respiratory rate 20, and oxygen saturation
100% on room air. Her laboratory values were signiﬁcant for elevated
C-reactive protein and CA-125 aswell as lowVitamin B12 andhemoglo-
bin (Table 1).
Non-contrast CT of the brain revealed an area of low attenuation
with mild mass effect within the right occipital region consistent with
an acute infarct. Brain magnetic resonance imaging (MRI) with and
without gadolinium revealed acute infarcts in the right greater than
left posterior cerebral artery distributions, involving the occipital
lobes, splenium of the corpus callosum, and right temporal lobe and
thalamus without hemorrhage or enhancing mass (Fig. 1) suggesting
a common proximal or embolic etiology. Magnetic resonance angiogra-
phy of the neck was negative for stenosis or occlusion. The patient was
diagnosed with acute infarcts of probable embolic etiology.
Embolic CVA workup included a trans-thoracic echocardiogram
(TTE), which revealed an ejection fraction (EF) of N55%without any sig-
niﬁcant cardiac valvular abnormalities. A subsequent trans-esophageal
echocardiogram (TEE) revealed a 1.8 × 0.8 cm mass on the anteriorFig. 1. Axial noncontrast CT at presentation (A) shows a low attenuation infarct in the right occ
weighted images (B, D) and low signal areas on the corresponding apparent diffusion coefﬁc
splenium of the corpus callosum (arrow, D) indicates compromise of the posterior perical
occipital lobe (arrowheads, D) indicate compromise of distal branches of the contralateral posleaﬂet of the mitral valve that was immobile and situated on the atrial
side of the valve. It was well circumscribed with mild-to-moderate mi-
tral valve regurgitation. Serial blood cultures to rule out infective endo-
carditis were negative. NBTEwas suspected, and the patientwas started
on enoxaparin 60 mg SQ BID.
Repeat brain MRI 2 weeks after initial presentation revealed evolv-
ing subacute infarcts in the right greater than left occipital lobes, parietal
lobes, posterior corpus callosum, and posterior mesial temporal lobes.
The patient's vision and memory improved gradually, but never
returned to baseline. A cardiac MRI revealed normal left ventricular
size and an EF of 69%. Follow-up TTE revealed an EF of 65% and thick-
ened mitral valve leaﬂets that opened well.
The patient re-initiated systemic therapy for advanced OCCC with
pemetrexed and bevacizumab followed by irinotecan and bevacizumab,
but unfortunately, her OCCC continued to progress. While on palliative
therapy for progressive disease, the patient remained on enoxaparin
and did not experience further embolic neurologic complications. The
patient died from end-stage OCCC 7 months following her NBTE
diagnosis.
3. Discussion
Thrombosis constitutes the most frequent complication and second
most common cause of death in cancer patients, with the emergence
of thromboembolic disease occasionally preempting the diagnosis of
malignancy, as ﬁrst noted by Trousseau in 1865 (Zacharski et al.,
1983; Rickles & Edwards, 1983). Malignancy promotes a prothrombotic
state in patients via aberrant production of tissue factor and cancer
procoagulant, such as interleukin 1β (IL-1β), tumor necrosis factor
alpha (TNF-α), and vascular endothelial growth factor (VEGF)
(Dranoff, 2004). TNF-α and IL-1β derived from malignant cells can in-
duce endothelial cells to increase tissue factor procoagulant activity
and to produce theﬁbrinolysis inhibitor plasminogen activator inhibitor
1. This accelerates the prothrombotic potential of endothelial cells in
malignancy. (Lee & Levine, 1999).
It is the hypercoagulable state of malignancy that is thought to per-
mit NBTE, (Aryana et al., 2006) a non-infectious endocarditis character-
ized by thrombi composed of immune complexes, mononuclear cells,
and ﬁbrin. NBTE more commonly involves the mitral (64%) and aortic
(25%) valves (Steiner, 1993), and is a complication that is mainly but
not exclusively associated with advanced malignancy. In a prospective
study of 200 cancer patients, echocardiographic evidence of NBTE was
identiﬁed in 19%, a prevalence 10 times higher than that of the control
population (Aryana et al., 2006). NBTE vegetations are prone to emboli-
zation and can involve multiple organ sites simultaneously. The most
common sites of embolization are the cerebrovascular, coronary, splen-
ic, pulmonary, and renal circulations (Aryana et al., 2006).
Cancer therapeutics can also enhance hypercoagulability. Our pa-
tient received bevacizumab as part of her adjuvant and maintenanceipital lobe (arrow). MRI demonstrates more extensive high signal areas on axial diffusion
ient maps (C, E) consistent with diffusion restriction and acute infarcts. Infarction in the
losal artery branch from the posterior cerebral artery, and punctate infarcts in the left
terior cerebral artery.
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debulking she discontinued anticoagulation therapy and received mul-
tiple systemic chemotherapy regimens including bevacizumab, which
in the absence of anticoagulation therapy may have contributed to hy-
percoagulability andNBTE. Bevacizumab in particular has been associat-
ed with arterial thromboembolism, and to a lesser extent venous
thromboembolism, in the setting of malignancy (Nalluri et al., 2008).
Bevacizumab, a recombinant humanized monoclonal antibody that
selectively binds to and neutralizes the biologic activity of human
VEGF has been shown to increase the risk of arterial thromboembolism
when administered with chemotherapy. In a study of 1745 patients
with metastatic breast, colorectal, or non-small cell lung carcinoma
treated with bevacizumab and chemotherapy versus chemotherapy
alone, the chemotherapy plus bevacizumab cohort had a signiﬁcantly
increased risk of developing arterial thromboembolism compared to
the chemotherapy-only group (Zacharski et al., 1983).
Treatment of NBTE consists of both anticoagulation and anti-cancer
therapy. Both IV and subcutaneous unfractionated heparin therapy
have been found to be effective in reducing the incidence of recurrence
of NBTE. Low-molecular-weight heparin may also be used, although
there is less evidence for its long-term efﬁcacy (el-Shami et al., 2007).
Vitamin K antagonists are less effective in controlling malignancy-
associated NBTE (Aryana et al., 2006; el-Shami et al., 2007). The effec-
tiveness of newer anticoagulants such as factor Xa and direct thrombin
inhibitors remains to be established. In this patient with prior PE, con-
tinuation of anticoagulation therapy could have prevented the develop-
ment of NBTE.
Adenocarcinoma of the ovary has been described as a cause for
NBTE, but OCCC presenting with NBTE is very rare. There are only
three published case reports on NBTE in OCCC. Systemic embolization
from NBTE to pulmonary, coronary, splenic, and renal territories as pre-
senting sequelae in a patient with stage IIC OCCC and without pulmo-
nary territory in a stage IC OCCC have been described (Aryana et al.,
2006). However, cerebrovascular infarcts in a patientwith clear cell car-
cinomawithNBTE has only been reported once thus far in a patientwith
stage IC OCCC who developed sudden onset left homonymous
hemianopsia following 6 cycles of adjuvant carboplatin and paclitaxel
chemotherapy (Devulapalli et al., 2012).
We report on a patient with advanced OCCC who presented with
acute cerebrovascular infarcts secondary to NBTE, a presentation that
has not been reported in the literature thus far. We also show that
NBTE can be controlled with appropriate anticoagulant therapy even
in the face of aggressive metastatic disease and concomitant use of
procoagulant anti-cancer therapy. NBTE is a serious and potentially
under-diagnosed manifestation of hypercoagulability in OCCC andshould be considered in all OCCC patients presentingwithmultiple em-
bolic events.
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